Side-by-side comparison of AI visibility scores, market position, and capabilities
Dutch health technology company with €17B revenue; MRI/CT imaging and patient monitoring managing massive sleep apnea device recall competing with Siemens Healthineers and GE HealthCare.
Philips is a Dutch multinational technology and health technology company that has transformed from a broad consumer electronics conglomerate into a focused health technology leader — producing diagnostic imaging systems (MRI, CT, ultrasound), patient monitoring, hospital informatics, personal health products (electric toothbrushes, shavers, sleep apnea devices), and health informatics solutions. Listed on the Amsterdam Stock Exchange (AEX: PHIA) and headquartered in Amsterdam, Philips generates approximately €17 billion ($18 billion) in annual revenue after divesting its lighting division (now Signify) and domestic appliances business.\n\nPhilips' health technology portfolio spans two segments: Diagnosis & Treatment (imaging systems, image-guided therapy, and ultrasound for hospitals) and Connected Care (patient monitoring, respiratory care, sleep therapy). The Diagnosis & Treatment segment provides MRI systems, CT scanners, and X-ray equipment to hospitals globally. The Connected Care segment includes Philips' DreamStation and other sleep apnea (CPAP/BiPAP) devices, home respiratory care, and hospital patient monitoring platforms.\n\nIn 2025, Philips is managing the severe consequences of a 2021 recall of approximately 5.5 million sleep apnea devices (Philips Respironics DreamStation and related models) due to concerns that degraded polyester foam could release harmful particles and gases — one of the largest medical device recalls in history. The recall has resulted in multi-billion dollar settlements, regulatory scrutiny, and significant reputation damage in the sleep therapy market, allowing competitors ResMed and Fisher & Paykel to gain share. Philips' 2025 strategy focuses on resolving recall liabilities, rebuilding the sleep therapy business, and investing in AI-powered diagnostic imaging to compete with Siemens Healthineers and GE HealthCare.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.